Mill Creek Capital Advisors LLC Buys 1,144 Shares of Johnson & Johnson (NYSE:JNJ)

Mill Creek Capital Advisors LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 248,661 shares of the company’s stock after acquiring an additional 1,144 shares during the quarter. Johnson & Johnson comprises about 0.9% of Mill Creek Capital Advisors LLC’s portfolio, making the stock its 18th biggest holding. Mill Creek Capital Advisors LLC’s holdings in Johnson & Johnson were worth $35,961,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently modified their holdings of the stock. First Fiduciary Investment Counsel Inc. lifted its position in shares of Johnson & Johnson by 2.9% during the 4th quarter. First Fiduciary Investment Counsel Inc. now owns 95,515 shares of the company’s stock valued at $13,813,000 after acquiring an additional 2,701 shares during the period. Pineridge Advisors LLC lifted its position in shares of Johnson & Johnson by 48.0% during the 4th quarter. Pineridge Advisors LLC now owns 780 shares of the company’s stock valued at $113,000 after acquiring an additional 253 shares during the period. Panoramic Capital Partners LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $715,000. Arlington Trust Co LLC lifted its position in shares of Johnson & Johnson by 15.3% during the 4th quarter. Arlington Trust Co LLC now owns 3,034 shares of the company’s stock valued at $439,000 after acquiring an additional 403 shares during the period. Finally, Global Wealth Management Investment Advisory Inc. lifted its position in shares of Johnson & Johnson by 6.8% during the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 33,957 shares of the company’s stock valued at $4,911,000 after acquiring an additional 2,171 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 1.3 %

Shares of JNJ stock opened at $157.24 on Friday. The stock has a market cap of $378.58 billion, a price-to-earnings ratio of 23.65, a PEG ratio of 2.46 and a beta of 0.52. The stock has a 50-day moving average of $147.58 and a 200-day moving average of $156.00. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.29 earnings per share. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.15%. Johnson & Johnson’s payout ratio is 74.59%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Morgan Stanley dropped their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Guggenheim upped their price objective on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Bank of America dropped their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.